CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

REGENXBIO Inc.

RGNX
$506MSmall Cap

Next catalyst

Phase 3December 2026

Ranibizumab (LUCENTIS®)

AMD

Get an email about RGNX's next catalysts

Track REGENXBIO (RGNX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

Plus 5 more upcoming events in our data (data readout, Phase 3 readout, PDUFA date and more).See the timeline

Catalyst Timeline

6 upcoming, 2 past

Phase 3Next

Ranibizumab (LUCENTIS®) Phase 3 Est. Readout (ATMOSPHERE)

December 2026~Ranibizumab (LUCENTIS®)671

Estimated primary completion for Ranibizumab (LUCENTIS®) trial (NCT04704921) in AMD. Topline data typically follows completion by weeks to months.

Source
Data Readout

Data Readout — Surabgene Lomparvovec

Dec 31, 2026

For Wet AMD. REGENXBIO announced an investor event on October 20, 2026 to discuss its surabgene lomparvovec clinical program for wet AMD ahead of anticipated topline pivotal data in 4Q 2026. The event will include clinical program overview and perspectives from retina specialists.

Source
Phase 3

Phase 3

January 2027~

Regenxbio announced that its Duchenne muscular dystrophy gene therapy met its primary endpoint in a pivotal study, with the company targeting FDA approval in 2027.

Source
PDUFA

FDA PDUFA Date RGX-121 (accelerated review)

February 2027~RGX-121

For Hunter syndrome. BLA submitted. AI-extracted from: REGENXBIO to resubmit application for Hunter gene therapy after FDA’s most recen

Source
PDUFA

FDA PDUFA Date Regenxbio gene therapy (unnamed)

May 2027~Regenxbio gene therapy (unnamed)

For Duchenne muscular dystrophy. BLA submitted. AI-extracted from: STAT+: Regenxbio says Duchenne gene therapy succeeded in clinical trial, paving

Source
BLA Filing

BLA Filing — RGX-202

Jul 1, 2027

For Duchenne muscular dystrophy. REGENXBIO reported Q2 2026 results with RGX-202 BLA submission for Duchenne muscular dystrophy on track for Q3 2026, targeting potential accelerated approval in 2H 2027. Long-term data for surabgene lomparvovec (ABBV-RGX-314) demonstrated durable safety and efficacy.

Source

How RGNX's past catalysts played out

Market Overview

Stock performance and key metrics

NASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaROCKVILLE

Clinical-stage biotechnology company developing AAV gene therapies

Drug Pipeline

Frequently asked questions

What is in REGENXBIO Inc.'s drug pipeline?→

CatalystAlert tracks 3 drug candidates in REGENXBIO Inc.'s (RGNX) pipeline across Phase 3, Phase 2. Its lead program is Aflibercept (EYLEA®) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is REGENXBIO Inc.'s next FDA catalyst?→

REGENXBIO Inc.'s (RGNX) next tracked catalyst is a Phase 3 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track RGNX biotech catalysts?→

Add RGNX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow REGENXBIO Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply